Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Intensity Therapeutics, Inc. ( (INTS) ).
On December 5, 2025, Intensity Therapeutics, Inc. announced it received a 180-day extension from Nasdaq to comply with the minimum $1.00 bid price requirement, following an initial compliance period that ended on December 3, 2025. The extension allows the company until June 1, 2026, to meet the requirement, with plans to monitor stock prices and consider a reverse stock split if necessary to maintain its Nasdaq listing. This extension does not immediately affect the company’s stock listing, but failure to comply could lead to delisting, impacting stakeholders and market perception.
The most recent analyst rating on (INTS) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Intensity Therapeutics, Inc. stock, see the INTS Stock Forecast page.
Spark’s Take on INTS Stock
According to Spark, TipRanks’ AI Analyst, INTS is a Underperform.
Intensity Therapeutics faces significant challenges typical of a pre-revenue biotech firm, including negative financial metrics and bearish technical indicators. While recent corporate announcements about cancer treatment progress are promising, they do not outweigh the financial and technical difficulties. The overall score reflects these challenges, positioning the stock at the lower end of the scoring range.
To see Spark’s full report on INTS stock, click here.
More about Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing novel intratumoral cancer therapies. Their proprietary technology aims to kill tumors and enhance immune system recognition of cancers. The company has conducted multiple clinical trials with its lead product candidate, INT230-6, which is designed for direct intratumoral injection and aims to improve cancer treatment outcomes.
Average Trading Volume: 30,426,268
Technical Sentiment Signal: Hold
Current Market Cap: $27.65M
For a thorough assessment of INTS stock, go to TipRanks’ Stock Analysis page.